| scholarly article | Q13442814 |
| P50 | author | Geertruida H de Bock | Q37842361 |
| Jakob de Vries | Q50868064 | ||
| Michael Schaapveld | Q51136548 | ||
| P2093 | author name string | Jan C Oosterwijk | |
| Marian J E Mourits | |||
| Dorina M van der Kolk | |||
| Annemieke H van der Hout | |||
| Beike K Leegte | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | breast cancer | Q128581 |
| ovarian cancer | Q172341 | ||
| P304 | page(s) | 643-651 | |
| P577 | publication date | 2010-03-04 | |
| P1433 | published in | Breast Cancer Research and Treatment | Q326085 |
| P1476 | title | Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. | |
| P478 | volume | 124 |
| Q38659629 | A comparison of cosegregation analysis methods for the clinical setting |
| Q90169827 | A nano-liposome formulation of the PARP inhibitor Talazoparib enhances treatment efficacy and modulates immune cell populations in mammary tumors of BRCA-deficient mice |
| Q85563319 | Acceptance of genetic counseling and testing in a hospital-based series of patients with gynecological cancer |
| Q36771826 | BRCA1/2 mutations perturb telomere biology: characterization of structural and functional abnormalities in vitro and in vivo |
| Q28085448 | Bias Correction Methods Explain Much of the Variation Seen in Breast Cancer Risks of BRCA1/2 Mutation Carriers |
| Q44602623 | Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations |
| Q40273462 | Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers |
| Q34590658 | Breast cancer genetic testing awareness, attitudes and intentions of Latinas living along the US-Mexico border: a qualitative study |
| Q50913863 | Breast cancer risk in Chinese women with BRCA1 or BRCA2 mutations. |
| Q35399596 | Breast cancer risks and risk prediction models |
| Q89476176 | Breast cancer: an update on treatment-related infertility |
| Q48219842 | Characterization of a novel germline BRCA1 splice variant, c.5332+4delA. |
| Q34738030 | Classifications within molecular subtypes enables identification of BRCA1/BRCA2 mutation carriers by RNA tumor profiling |
| Q35687632 | Clinical Considerations of BRCA1- and BRCA2-Mutation Carriers: A Review |
| Q26744320 | Contralateral prophylactic mastectomy: current perspectives |
| Q51346860 | Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer. |
| Q26749389 | Decision-Making in the Surgical Treatment of Breast Cancer: Factors Influencing Women's Choices for Mastectomy and Breast Conserving Surgery |
| Q50094892 | Detection of Germline Mutations in Patients with Epithelial Ovarian Cancer Using Multi-Gene Panels: Beyond BRCA1/2. |
| Q38830488 | Earlier Age of Breast Cancer Onset in Israeli BRCA Carriers-Is it a Real Phenomenon? |
| Q93165324 | Effects of BRCA Germline Mutations on Triple-Negative Breast Cancer Prognosis |
| Q36242941 | Elevated Bone Turnover Markers after Risk-Reducing Salpingo-Oophorectomy in Women at Increased Risk for Breast and Ovarian Cancer |
| Q34708560 | Epithelial ovarian cancer: An overview |
| Q48506802 | Fertility preservation in women harboring deleterious BRCA mutations: ready for prime time? |
| Q36915151 | Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer |
| Q34508273 | Functional characterization of BRCA1 gene variants by mini-gene splicing assay |
| Q34425230 | Hereditary breast cancer: clinical, pathological and molecular characteristics |
| Q88847665 | Hereditary breast cancer: molecular biology and management update |
| Q91630403 | How Should Genetic Counseling for Ovarian Cancer Be Implemented in a Middle-Income Country? An Insight Based on the Brazilian Scenario |
| Q28271817 | Identification of six pathogenic RAD51C mutations via mutational screening of 1228 Danish individuals with increased risk of hereditary breast and/or ovarian cancer |
| Q37594381 | Impact of rapid genetic counselling and testing on the decision to undergo immediate or delayed prophylactic mastectomy in newly diagnosed breast cancer patients: findings from a randomised controlled trial |
| Q36955208 | Implications of using whole genome sequencing to test unselected populations for high risk breast cancer genes: a modelling study |
| Q40247920 | Inverse birth cohort effects in ovarian cancer: Increasing risk in BRCA1/2 mutation carriers and decreasing risk in the general population. |
| Q33885464 | Lifestyle Risk Factors for Breast Cancer in BRCA1/2-Mutation Carriers Around Childbearing Age. |
| Q37692442 | Lower mitotic activity in BRCA1/2-associated primary breast cancers occurring after risk-reducing salpingo-oophorectomy |
| Q33908246 | Map making in the 21st century: charting breast cancer susceptibility pathways in rodent models |
| Q38087850 | Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers |
| Q36717818 | Migrant breast cancer patients and their participation in genetic counseling: results from a registry-based study. |
| Q53433793 | Mindfulness, cognitive behavioural and behaviour-based therapy for natural and treatment-induced menopausal symptoms: a systematic review and meta-analysis. |
| Q48005561 | Molecular determination of the clonal relationships between multiple tumors in BRCA1/2-associated breast and/or ovarian cancer patients is clinically relevant |
| Q92281916 | Mortality and Risk of Cancer After Prophylactic Bilateral Oophorectomy in Women With a Family History of Cancer |
| Q26773609 | Oncological safety of prophylactic breast surgery: skin-sparing and nipple-sparing versus total mastectomy |
| Q57110065 | Prophylactic mastectomy for the prevention of breast cancer: Review of the literature |
| Q51245901 | Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: a national cohort study. |
| Q52724999 | Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study. |
| Q35203528 | Splicing analysis of 14 BRCA1 missense variants classifies nine variants as pathogenic |
| Q40758851 | Surgeons' Perspectives of Contralateral Prophylactic Mastectomy |
| Q38190905 | Surgical management of breast cancer in BRCA-mutation carriers: a systematic review and meta-analysis |
| Q91858202 | Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers |
| Q34113473 | Survival and contralateral breast cancer in CHEK2 1100delC breast cancer patients: impact of adjuvant chemotherapy |
| Q50061760 | The Shifting Paradigm for Breast Cancer Surgery in Patients Undergoing Neoadjuvant Chemotherapy |
| Q35018746 | The breast cancer susceptibility genes (BRCA) in breast and ovarian cancers |
| Q36240959 | The effect of personal medical history and family history of cancer on the uptake of risk-reducing salpingo-oophorectomy |
| Q34481713 | The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/BRCA2 mutation carriers: Implications for counseling |
| Q35251010 | Therapeutic targeting of BRCA1-mutated breast cancers with agents that activate DNA repair |
| Q30896495 | Timing of risk reducing mastectomy in breast cancer patients carrying a BRCA1/2 mutation: retrospective data from the Dutch HEBON study |
| Q37187461 | Where genotype is not predictive of phenotype: towards an understanding of the molecular basis of reduced penetrance in human inherited disease |
| Q36889714 | Which screening strategy should be offered to women with BRCA1 or BRCA2 mutations? A simulation of comparative cost-effectiveness. |
Search more.